All studies
Not yet recruitingPhase IVInterventional

Comparing the clinical and cost-effectiveness of colesevelam for bile acid diarrhoea with colestyramine or loperamide, including long-term follow-up

Primary bile acid diarrhoea (pBAD) happens when extra bile acid enters the large bowel, leading to sudden, watery stools. While the condition affects around 1 in 100 people in the UK, it is often mistaken for irritable bowel syndrome (IBS). The NHS uses three main medicines to treat pBAD: colesevelam, colestyramine, and loperamide. However, doctors do not yet know which of these three works best or offers the best value for money. The COBALT study aims to answer this question. Adults newly diagnosed with pBAD will track their bowel habits and be randomly chosen to take one of the three medicines for six months. Researchers will follow their health for 12 months using surveys, diaries, and simple blood tests. The findings will help doctors choose the best treatments for people with pBAD across the UK.

At a glance

Status
Not yet recruiting
Phase
Phase IV
Sponsor
University of Birmingham
Enrolment target
519
Start
03 Dec 2026
Estimated completion
30 Sep 2028

What is this study about?

Primary bile acid diarrhoea (pBAD) is a gut condition that causes frequent, watery, and urgent bowel movements. It happens when bile acids—natural digestive juices made by the liver—are not properly reabsorbed and leak into the large bowel. This irritates the bowel lining and draws in extra water. Many people live with difficult symptoms like sudden toilet urgency or accidental bowel leakage for years before getting a clear diagnosis.

At present, NHS doctors use several well-known medicines to help manage pBAD. These include bile acid binders (colesevelam and colestyramine) and anti-diarrhoea medicines (loperamide). While all three can help control symptoms, doctors lack clear evidence showing which one provides the best symptom relief, is easiest to take, and gives the NHS the best value for money.

The COBALT clinical trial is designed to solve this puzzle. By directly comparing colesevelam, colestyramine, and loperamide in patients who have been recently diagnosed, researchers hope to see which medicine gives people the greatest control over their bowels and the highest quality of life.

Finding the most effective treatment could transform care across the UK. It means future patients may receive the right medicine much sooner, helping them get back to work, socialise comfortably, and live without the daily worry of sudden diarrhoea.

Key takeaways

  • The COBALT study compares three standard NHS treatments for bile acid diarrhoea to see which works best.
  • Open to UK adults diagnosed with primary bile acid diarrhoea via a SeHCAT scan in the last six weeks.
  • Participants take colesevelam, colestyramine, or loperamide for six months, with a choice to continue or switch for another six months.
  • Total study follow-up lasts 12 months, using symptom diaries, surveys, and two blood tests.
  • All three drugs are safe, widely used NHS medicines, not new experimental drugs.

Who may be eligible?

You may be eligible for this study if you are 18 or older and were diagnosed with primary bile acid diarrhoea within the last six weeks using a routine NHS nuclear medicine scan known as a SeHCAT test. You should also have had frequent, loose stools (averaging three or more bowel motions a day) for at least the past six months.

To keep results clear and ensure patient safety, certain people cannot take part. You cannot join if you have already taken bile acid binders, or if your diarrhoea is caused by other conditions like coeliac disease, Crohn's disease, ulcerative colitis, or pancreas problems. Having past surgery on your bowel, gallbladder, or stomach also excludes you from taking part.

In addition, people currently taking daily strong opioid painkillers, certain weight-loss or diabetes injections (such as GLP-1 medicines), or long-term preventative antibiotics are not eligible. Pregnant or breastfeeding women cannot join the study at this time.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I was diagnosed with primary bile acid diarrhoea in the last six weeks via a SeHCAT scan.
  3. I have had frequent, watery, or loose bowel motions for at least six months.
  4. I have not previously taken bile acid binder medicines (like colestyramine or colesevelam).
  5. I have never had surgery on my gallbladder, bowel, or stomach.
  6. I am not currently pregnant, trying for a baby, or breastfeeding.
Answer every question to see your result.

What does participation involve?

If you wish to take part, you will start by keeping a 14-day diary of your daily bowel movements to confirm the study is suitable for you. If you qualify, you will visit your local hospital clinic to give consent, have routine health checks, and provide a small blood sample.

You will then be randomly assigned by a computer to take one of three medicines: colesevelam, colestyramine, or loperamide. Neither you nor your doctor can pick which one you get. You will take this medicine for six months. At your six-month hospital visit, you can choose to stay on your assigned medicine or switch to a different standard treatment for another six months.

Your total time in the study will be 12 months. Throughout the year, you will complete short diaries and questionnaires about your symptoms, everyday activities, and general wellbeing. Most of these updates can be done from home by phone, online, or on paper. A second blood test will be taken at the six-month mark.

Potential risks and benefits

Taking part may help improve your diarrhoea symptoms, though an improvement cannot be guaranteed. Your participation will help doctors understand how best to treat future patients with pBAD. All three medicines are already widely used in the NHS, but they can cause mild side effects such as constipation, stomach ache, bloating, sickness, or headaches. Having blood taken may cause brief stinging or a small bruise. Joining the trial also involves the time and effort needed to fill in diaries and collect medication. Taking part is completely voluntary, and you can leave the study at any time without your regular NHS medical care being affected.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • Not provided at time of registration
    Unverified
    -, England

Common questions

Can I choose which of the three medicines I take?

No. A computer randomly decides which medicine you receive to make sure the trial is fair and scientifically accurate.

Are the study medicines new or experimental?

No. All three medicines (colesevelam, colestyramine, and loperamide) are already routinely prescribed on the NHS to treat diarrhoea.

What happens if I get unpleasant side effects?

The study team will monitor you closely. If you experience uncomfortable side effects, your study doctor can adjust your dose or stop the medicine.

Do I have to travel to the hospital for every check-up?

No. Aside from a few essential hospital appointments for blood tests and health reviews, many questionnaires can be completed from home online, on paper, or over the telephone.

Can I leave the trial if I change my mind?

Yes. You are free to withdraw from the study at any point without giving a reason, and it will not change the standard of your ongoing NHS care.

How to find out more

Becky Case

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "Comparing the clinical and cost-effectiveness of colesevelam…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.